Intestinal inflammation and impact on growth in children with cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 4, 2015, Pages 521-526

  Dhaliwal, Jasbir ^a   Leach, Steven ^b   Katz, Tamarah ^c   Nahidi, Lily ^d   Pang, Tamara ^b   Lee, J M ^b   Strachan, Roxanne ^a   Day, Andrew S ^e   Jaffe, Adam ^b   Ooi, Chee Y ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Nutrition and Dietetics ^*  (Australia)

^d Clinical Trials Centre   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

calprotectin; growth; gut inflammation; nutrition; osteoprotegerin; S100A12

Indexed keywords

CALGRANULIN; OSTEOPROTEGERIN; PROTEIN; S100A12 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALGRANULIN C;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD GROWTH; CHILD NUTRITION; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENTERITIS; FECES LEVEL; FEMALE; GENOTYPE; HUMAN; MALE; NUTRITIONAL STATUS; PHENOTYPE; PRIORITY JOURNAL; CHEMISTRY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; GROWTH; GROWTH DISORDERS; INFLAMMATION; INTESTINE; METABOLISM; PANCREAS EXOCRINE INSUFFICIENCY; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; FEMALE; GROWTH; GROWTH DISORDERS; HUMANS; INFLAMMATION; INTESTINES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; OSTEOPROTEGERIN; S100A12 PROTEIN;

EID: 84927173806     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000683     Document Type: Article

References (41)

1. Anderson DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938;56:344.
2. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-14.
3. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. Curr Opin Pulm Med 2002;8:S542-6.
4. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009;119:2613-22.
5. De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Pathol 2007;293:G104-11.
6. Gustafsson JK, Ermund A, Ambort D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 2012;209:1263-72.
7. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004;72:6040-9.
8. De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007;293:G577-84.
9. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000;82:394-9.
10. Werlin SL, Benuri-Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;51:304-8.
11. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/A9) and S100A12 are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1321-31.
12. Nahidi L, Leach S, Sidler M, et al. Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. Inflamm Bowel Dis 2011;17:516-23.
13. Bjerke K, Halstensen TS, Jahnsen F, et al. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357-63.
14. Vogl T, Pröpper C, Hartmann M, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999;274:25291-6.
15. Kaiser T, Langhorst J, Wittkowski H, et al. Fecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13.
16. Vidal K, Serrant P, Schlosser B, et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol 2004; 287:G836-44.
17. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-87.
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179.
19. Wang SS, O'Leary LA, Fitzsimmons SC, et al. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002;141:80.
20. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Infllamm Bowel Dis 2008;14:359-66.
21. Nahidi L, Leach ST, Sidler MA, et al. Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. Inflamm Bowel Dis 2011;17:516-23.
22. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653-74.
23. Nahidi L, Leach S, Lemberg D, et al. Osteoprotegerin exerts its proinflammatory effects through nuclear factor-kB activation. Dig Dis Sci 2013;58:3144-55.
24. Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS ONE 2014;9:e87796.
25. Schippa S, Iebba V, et al. CFTR allelic variants relate to shifts in fecal microbiota of cystic fibrosis patients. PLoS ONE 2013;8:e61176.
26. Duytschaever G, Huys G, Bekaert M, et al. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol 2011;77:8015-24.
27. Duytschaever G, Huys G, Bekaert M, et al. Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros 2013;12:206-15.
28. Madan JC, Koestle DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio 2012;3:e00251-312.
29. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011;11:7.
30. Gelfond D, Ma C, Semler J, et al. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci 2013;58:2275-81.
31. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. J Nature 2012;487:109-11.
32. Sakata H, Fujita K, Yoshioka H. The effect of antimicrobial agents on fecal flora of children. Antimicrob Agents Chemother 1986;29:225-9.
33. Mack DR, Flick JA, Durie PR, et al. Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction. J Pediatr 1992; 120:696-701.
34. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010;2:29ra31.
35. De Lisle RC, Meldi L, Flynn M, et al. Altered eicosanoid metabolism in the cystic fibrosis mouse small intestine. J Pediatr Gastroenterol Nutr 2008;47:406-16.
36. Zemel BS, Jawad AF, FitzSimmons S, et al. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 2000;137:374-80.
37. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219-25.
38. Rowe SM, Heltshe SL, Gonska T, et al. Van. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator Ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014;190:175-84.
39. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9.
40. Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010;9:193-8.
41. Foell D, Seeliger S, Vogl T, et al. Expression of S100A12 (ENRAGE) in cystic fibrosis. Thorax 2003;58:613-7.